Indivior

Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange.

Indivior
Public company
Traded asLSE: INDV
Industrypharmaceuticals
Founded1994
HeadquartersRichmond, Virginia
Key people
Howard Pien, Chairman
Shaun Thaxter, CEO
ProductsSubutex/Subuxone
Revenue$1,005 million (2018)[1]
$292 million (2018)[1]
$275 million (2018)[1]
Number of employees
915 (2018)[1]
Websitewww.indivior.com/

History

The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]

In 2019, Indivior was indicted over claims that it had made false marketing claims about the effectiveness of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with the Justice Department to pay $1.4 billion to resolve a U.S. Federal investigation into sales and marketing of opioid addiction treatment.[5][6][7]

Operations

The company's main products are Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction.[2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[8]

  • Suboxone sublingual film

References
  1. "Annual Report 2018" (PDF). Indivior. Retrieved 18 March 2019.
  2. "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
  5. Reuters (11 July 2019). "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. ISSN 0362-4331. Retrieved 11 July 2019.
  6. admin. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Retrieved 11 July 2019.
  7. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. 11 July 2019. Retrieved 11 July 2019.
  8. "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.